Effect of Uridine 5′-Triphosphate Plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 153, Issue 6 I, 1996, Pages 1796-1801

  Bennett, W D ^a,b   Olivier, K N ^a   Zeman, K L ^a   Hohneker, K W ^a   Boucher, R C ^a   Knowles, M R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; URIDINE TRIPHOSPHATE;

ADULT; ARTICLE; BRONCHUS MUCOSA; BRONCHUS SECRETION; CHLORIDE TRANSPORT; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG CLEARANCE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MUCOCILIARY CLEARANCE; PRIORITY JOURNAL; SODIUM TRANSPORT;

ADULT; AEROSOLS; AMILORIDE; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MUCOCILIARY CLEARANCE; TIME FACTORS; TREATMENT OUTCOME; URIDINE TRIPHOSPHATE;

EID: 0029887172     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.153.6.8665037     Document Type: Article

References (26)

1. Quinton, P. M. 1990. Cystic fibrosis: a disease in electrolyte transport. F.A.S.E.B. J. 4:2709-2717.
2. Boucher, R. C., E. H. C. Cheng, A. M. Paradiso, M. J. Stutts, M. R. Knowles, and H. S. Earp. 1989. Chloride secretory response of cystic fibrosis human airway epithelia: preservation of calcium but not protein kinase C- and A-dependent mechanisms. J. Clin. Invest. 84:1424-1431.
3. Boucher, R. C., M. J. Stutts, M. R. Knowles, L. Cantley, and J. T. Gatzy. 1986. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J. Clin. Invest. 78:1245-1252.
4. Davis, P. B. 1993. Pathophysiology of the lung disease in cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Lung Biology in Health and Disease, Vol. 64. Marcel Dekker, New York, 193-218.
5. Knowles, M. R., N. L. Church, W. E. Waltner, J. R. Yankaskas, P. H. Gilligan, M. King, L. J. Edwards, R. W. Helms, and R. C. Boucher. 1990. A pilot study of aerosolized amiloride for the treatment of cystic fibrosis lung disease. N. Engl. J. Med. 322:1189-1194.
6. Knowles, M. R., L. L. Clarke, and R. C. Boucher. 1991. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325:533-577.
7. Mason, S. J., A. M. Paradiso, and R. C. Boucher. 1991. Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human and cystic fibrosis airway epithelium. Br. J. Pharmacol. 103:1649-1656.
8. 2+ and cAMP. Am. J. Physiol. 263:L232-L242.
9. Lethem, M. I., M. L. Dowell, M. Van Scott, J. R. Yankaskas, T. Egan, R. C. Boucher, and C. W. Davis. 1993. Nucleotide regulation of goblet cells in human airway epithelial explants: normal exocytosis in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 9:315-322.
10. Olivier, K. N., W. D. Bennett, K. W. Hohneker, K. L. Zeman, L. J. Edwards, R. C. Boucher, and M. R. Knowles. 1996. Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate ± amiloride in normal human adults. Am. J. Respir. Crit. Care Med. (In press)
11. Regnis, J. A., M. Robinson, D. L. Bailey, P. Cook, P. Hooper, H. K. Chan, I. Gonda, G. Bautovich, and P. T. P. Bye. 1994. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150:66-71.
12. Mason, S. J., K. N. Olivier, D. Bellinger, D. J. Meuten, P. D. Pare, M. R. Knowles, and R. C. Boucher. 1993. Studies of absorption and acute and chronic effects of aerosolized and parenteral uridine 5′-triphosphate (UTP) in animals (abstract). Am. Rev. Respir. Dis. 147:A27.
13. Bennett, W. D., W. F. Chapman, and J. M. Mascarella. 1993. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 103:488-495.
14. May, K. R. 1949. An improved spinning top homogeneous spray apparatus. J. Appl. Phys. 20:932-938.
15. Wales, K. A., H. Petrow, and D. B. Yeates. 1980. Production of Tc99m-labeled iron oxide aerosols for human lung deposition and clearance studies. Int. J. Appl. Radiat. Isot. 31:689-694.
16. Ilowite, J. S., G. C. Smaldone, R. Perry, W. D. Bennett, and W. M. Foster. 1989. The relationship between tracheobronchial clearance rates and sites of initial deposition in man. Arch. Environ. Health 44:267-273.
17. Smaldone, G. C., W. M. Foster, T. G. O'Riordan, M. S. Messina, R. J. Perry, and E. G. Langenback. 1993. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 103: 1390-1396.
18. Rossman, C. M., R. Waldes, D. Sampson, and M. T. Newhouse. 1982. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am. Rev. Respir. Dis. 126:131-135.
19. Scherer, P. W. 1980. Mucus transport by cough. Chest 80:830-833.
20. Sanchis, J., M. Dolovich, C. Rossman, W. Wilson, and M. Newhouse. 1973. Pulmonary mucociliary clearance in cystic fibrosis. N. Engl. J. Med. 288:651-554.
21. Ilowite, J. S., J. D. Gorvoy, and G. C. Smaldone. 1987. Quantitative deposition on aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136:1445-1449.
22. Smaldone, G. C., R. Perry, W. D. Bennett, M. Messina, J. Zwang, and J. Ilowite. 1988. Interpretation of 24 hr lung retention in studies of mucociliary clearance. J. Aerosol Med. 1:11-20.
23. App, E. M., M. King, R. Helfesrieder, D. Kohler, and H. Matthys. 1990. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. Am. Rev. Respir. Dis. 141:605-612.
24. Curtis, L. N., and D. W. Misch. 1984. Regulation of mucociliary transport: response of mucous cells to stimulation by amiloride applied to the frog palate in vitro. Am. Rev. Respir. Dis. 129:816-822.
25. Cushley, M. J., A. E. Tattersfield, and S. T. Holgate. 1983. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br. J. Clin. Pharmacol. 15:161-165.
26. Gaba, S. J. M., and C. Prefaut. 1990. Comparison of pulmonary and systemic effects of adenosine triphosphate in chronic obstructive pulmonary disease. ATP: a pulmonary controlled vasoregulator? Eur. Respir. J. 3:450-455.